U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1916
    -0.0063 (-0.52%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • USD/JPY

    108.3600
    +0.3840 (+0.36%)
     
  • BTC-USD

    49,460.12
    +803.46 (+1.65%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Galapagos NV (GLPG) Investigation

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / January 5, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Galapagos NV ("Galapagos" or the "Company") (NASDAQ:GLPG). Investors who purchased Galapagos securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/glpg.

The investigation concerns whether Galapagos and certain of its officers and/or directors have violated federal securities laws.

On August 18, 2020, Galapagos disclosed that Galapagos's collaborative partner, Gilead Sciences, Inc. ("Gilead"), had received a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") for the New Drug Application ("NDA") for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis. Galapagos advised investors that "[t]he FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose." On this news, Galapagos's stock price fell $47.07 per share, or 25.03%, to close at $141.00 per share on August 19, 2020.

If you are aware of any facts relating to this investigation, or purchased Galapagos shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/glpg. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/623164/Bronstein-Gewirtz-Grossman-LLC-Reminds-Shareholders-of-Galapagos-NV-GLPG-Investigation